ICL’s growth engine drives sales to $2.1 billion

• ICL’s second-quarter sales increased 17% to $2.14 billion, while operating income rose to $266 million.
• Adjusted EBITDA climbed 28% to $448 million, and adjusted diluted earnings reached $0.12 per share.
• ICL plans to reorganize its operations in 2027 and targets more than $350 million in annual cost savings by 2028.

ICL (NYSE:ICL) reported second-quarter sales of $2.14 billion, up 17%, as all four operating segments recorded revenue growth.

Operating income increased 47% to $266 million, adjusted EBITDA rose 28% to $448 million and shareholder net income climbed 47% to $137 million.

“ICL exceeded expectations in the second quarter and reported solid growth across all key financial metrics,” said ICL President and CEO Elad Aharonson.

Operating cash flow increased to $290 million, free cash flow rose 34% to $94 million and the board declared a dividend of $0.0581 per share.

Following the announcement, ICL's share price was unchanged at $5.09 in extended trading before the U.S. market opened.

ICL said it intends to reorganize its operations in early 2027 into Nutrition Solutions, Industrial Products, Growing Solutions and Essential Minerals divisions.

The company said its Elevate cost-reduction programme is expected to generate more than $350 million in annualised savings by the end of 2028.